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Reactive oxygen species (ROS)
Dicarboxylates
Atpenin A5The impact of complex II (succinate:ubiquinone oxidoreductase) on the mitochondrial production of reactive
oxygen species (ROS) has been underestimated for a long time. However, recent studies with intact mito-
chondria revealed that complex II can be a signiﬁcant source of ROS. Using submitochondrial particles from
bovine heart mitochondria as a system that allows the precise setting of substrate concentrations we could
show that mammalian complex II produces ROS at subsaturating succinate concentrations in the presence
of Q-site inhibitors like atpenin A5 or when a further downstream block of the respiratory chain occurred.
Upon inhibition of the ubiquinone reductase activity, complex II produced about 75% hydrogen peroxide
and 25% superoxide. ROS generation was attenuated by all dicarboxylates that are known to bind competi-
tively to the substrate binding site of complex II, suggesting that the oxygen radicals are mainly generated
by the unoccupied ﬂavin site. Importantly, the ROS production induced by the Q-site inhibitor atpenin A5
was largely unaffected by the redox state of the Q pool and the activity of other respiratory chain complexes.
Hence, complex II has to be considered as an independent source of mitochondrial ROS in physiology and
pathophysiology.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Themitochondrial respiratory chain not only provides themain por-
tion of ATP in mammalian cells, but also is a major source of reactive
oxygen species (ROS) [1–3].While an increasedmitochondrial ROS pro-
duction has been mainly associated with several pathophysiological
conditions, it is increasingly evident that ROS produced under physio-
logical conditions can also serve as essential signaling molecules [4,5].
Within the respiratory chain, complexes I (NADH:ubiquinone oxidore-
ductase) and III (cytochrome bc1 complex; ubiquinol:cytochrome c ox-
idoreductase) are generally regarded as the main generators of ROS
[1–3,6], whereas a contribution of complex II seemed to be negligible.
On the other hand, it has been recognized that complex II activity can
modulate the ROS production of complexes I and III under speciﬁc con-
ditions (overview in [7]). A high succinate concentration/complex II ac-
tivity is the prerequisite to induce superoxide production at complex I
due to reverse electron transfer (RET) [8–12]. Additionally, complex II
activity can inﬂuence the antimycin A induced superoxide production; FAD, ﬂavin adenine dinucleo-
/reduced from of nicotinamide
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l rights reserved.at the Qo site of complex III [13,14] that is maximal at intermediate
redox-states of the Q-pool [15,16].
Several studies have shown that mammalian complex II produces
hardly any ROS at saturating succinate concentrations in isolated mi-
tochondria or submitochondrial particles (SMP) [13,17,18]. However,
a malfunction of complex II has been associated with different patho-
physiological conditions including speciﬁc forms of cancer and it
seems plausible that disease-associated mutations increase the mito-
chondrial ROS production [19–23]. Otherwise, complex II Q-site inhibi-
tors have been used to speciﬁcally induce cell death of cancer cells
which also involves the production of ROS (reviewed in [24,25]).
Hence, understanding the complicated intertwining connection be-
tween complex II and mitochondrial ROS production is essential to
clarify its role in physiology and pathophysiology [7].
The primary physiological function of complex II is to oxidize succi-
nate to fumarate and transfer the electrons derived from this reactions
onto ubiquinone that fuels thedownstream respiratory chain complexes
III and IV [26]. This reaction sequence creates a direct link between two
major energy-convertingmitochondrial pathways, the tricarboxylic acid
cycle (TCA or Krebs cycle) and the respiratory chain. The catalytic mech-
anism and the structural organization of complex II are well known
[26,27]. The succinate oxidation takes place in the dicarboxylate binding
site of the matrix-facing SdhA-subunit and involves a covalently bound
FAD. The electrons are transferred via three iron–sulfur clusters (located
in SdhB) to the (proximal) ubiquinone binding (Q-site) site located at
the interface between SdhB and the two membrane-bound subunits
SdhC and SdhD. The two membrane-bound subunits additionally bind
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cofactors and does not contribute to the electron transfer between the
two substrate binding sites [27].
It has been shown that the structurally and functionally related bac-
terial succinate:quinoneoxidoreductases (SQR) (overview in [19,26,27])
and especially the quinol:fumarate oxidoreductases (QFR) can be a
major source of ROS under aerobic conditions [28,29]. In a detailed anal-
ysis, Messner and Imlay [29] observed a bell-shaped dependence of the
succinate-fueled ROS-production by SOR and QFR from Escherichia coli
that peaked at a substrate concentration around 1 mM. While the
E. coli SQR produced only superoxide, the QFR produced a mixture of
superoxide and hydrogen peroxide [29]. Recently, Quinlan and col-
leagues could show that also the mammalian complex II can produce
ROS at signiﬁcant rates if the downstream respiratory chain is blocked
[30]. Maximal ROS production occurred in isolated skeletal muscle
mitochondria at concentrations of ~400 μM succinate while a saturating
concentration largely suppressed the ROS release [30]. The authors con-
cluded that the ROS generation occurs at the ﬂavin in the unoccupied
dicarboxylate binding site (also called site IIF).
In the present investigation, we used submitochondrial particles de-
rived from bovine heartmitochondria to investigate the ROS generation
of complex II in more detail. We conﬁrmed that complex II produces
ROS at subsaturating succinate concentrations in the presence of
Q-site inhibitors like atpenin A5 or when a further downstream block
of the respiratory chain occurred. Upon inhibition of the ubiquinone re-
ductase activity, complex II mainly produced hydrogen peroxide. The
ROS production was reduced not only by higher succinate concentra-
tions, but also by other TCA cycle intermediates that are known to
bind competitively to the dicarboxylate binding site. Finally, the atpenin
A5 induced ROS production was largely unaffected by the activity of
other respiratory chain complexes which indicates that complex II is
an independently inducible mitochondrial ROS generator.
2. Material and methods
2.1. Materials
DQA (2-n-decyl-quinazolin-4-yl-amine, SAN 549) was a gener-
ous gift from Prof. Ulrich Brandt (Radboud University Nijmegen,
The Netherlands), atpenin A5 was from Enzo Life Sciences (Lörrach,
Germany). Since diluted atpenin A5 solutions have a limited stability,
they were freshly prepared from a 1 mM stock before starting the
experiments. Ampliﬂu Red™ (10-acetyl-3,7-dihydroxyphenoxazine),
HRP, SOD (from bovine liver), antimycin A, stigmatellin, diazoxide,
TTFA and all other chemicals were from Sigma-Aldrich (Steinheim,
Germany).
2.2. Preparation of SMP
Submitochondrial particles from bovine heart mitochondria were
prepared as previously described [31]. The preparation that was
used throughout this investigation had a protein concentration of
32.0 mg/ml (29.8 μM haem b and 37.5 μM haem aa3).
2.3. Measurements of superoxide and H2O2 production
The production of reactive oxygen species (superoxide and hydro-
gen peroxide) was generally measured in a Spectra Max Plus384
microplate reader (Molecular Devices) at 37 °C by absorbance with
the exception of the data presented in Fig. 1B that were measured
in a Spectra Max M2e Multi Mode Reader (Molecular Devices). SMP
(24 μg protein per cavity; total assay volume 200 μl) were dissolved
in a buffer containing 75 mM sodium phosphate, 1 mM EDTA, and
1 mM MgCl2 (pH 7.2) supplemented with 400 U ml−1 SOD. In some
experiments, the pH was raised to 8.0. SOD supplementation was
necessary to ensure the complete conversion of superoxide tohydrogen peroxide (SOD increased the detected rate of H2O2 produc-
tion by ~20%) and to reduce the NADH-dependent background reaction
of HRP with 10-acetyl-3,7-dihydroxyphenoxazine [32,33]. The respira-
tory chain of the SMP was usually fueled with different succinate con-
centrations (0.01–5.0 mM) and/or 250 μM NADH. Background rates
were determined in the absence of SMP. In general, triplicates of all
data points were acquired and the mean value and standard deviation
are shown. Respiratory chain inhibitors (complex I: DQA; complex II:
Q-site — atpenin A5, dicarboxylate site — malonate; complex III Qo
site: stigmatellin) and different TCA cycle intermediates (fumarate;
oxaloacetate; malate; citrate) were applied as indicated. The hydrogen
peroxide production was measured by the HRP (0.1 U ml−1) catalyzed
conversion of 50 μM 10-acetyl-3,7-dihydroxyphenoxazine (Amplifu
Red™, also called Amplex Red®) to resoruﬁn [34] that can be followed
at the absorption maxima of 571 nm (ε571 nm: 54 mM−1 cm−1) [33].
Kinetic data were usually recorded for 20 min at an interval of
13 readings min−1. The superoxide production was monitored as the
SOD-sensitive reduction of acetylated cytochrome c [35] at Δ550–
540 nm, i.e. the reduction of 25 μM acetylated cytochrome c was
measured in the absence and presence of 400 U ml−1 SOD and the dif-
ference was used to calculate the rate (ε550–540 nm: 19.1 mM−1 cm−1)
[36]. Kinetic data were usually recorded for 10 min at an interval of
13 readings min−1.
2.4. High-resolution respirometry
The effect of various substances on the succinate-oxidase and
NADH-oxidase was monitored at 37 °C using an Oxygraph-2k system
(Oroboros, Innsbruck, Austria), equipped with two chambers and
DatLab software version 4.2. We matched exactly the conditions (es-
pecially the molar ratio of SMP and applied inhibitors) to the
corresponding ROS measurements. Therefore, SMP were applied at
240 μg protein to 2 ml buffer containing 75 mM sodium phosphate,
1 mM EDTA, and 1 mM MgCl2 (pH 7.2). The succinate-oxidase was
usually measured with 100 μM succinate, the NADH-oxidase with
250 μM NADH as substrates. The activity in the presence of the
respective inhibitor concentrations was related to the uninhibited
oxygen-consumption. Shown are mean values of duplicates.
3. Results
3.1. Mammalian complex II produces ROS at subsaturating succinate
concentrations upon inhibition of the ubiquinone reductase activity
Recently, Quinlan and colleagues could show that mammalian
complex II can be a major source of reactive oxygen species when
the downstream respiratory chain is blocked [30]. In their investiga-
tion with isolated skeletal muscle mitochondria they observed that
the ROS generation, measured as the release of hydrogen peroxide,
was maximal at subsaturating succinate concentrations (peak at
~400 μM) and that it was almost completely suppressed by saturating
concentration of the dicarboxylate. In a ﬁrst set of experiments, we
checked if complex II in uncoupled submitochondrial particles from
bovine heart mitochondria produces ROS under corresponding condi-
tions. To gain mechanistic insight into the ROS-production by com-
plex II, uncoupled SMP as a model system have the advantages that
(1) the determination of the ROS production is not attenuated by
the antioxidative defence systems that are present in the matrix of
mitochondria, (2) both H2O2 and superoxide production can be quan-
tiﬁed, (3) the substrate concentration can be reliably adjusted (in
intact mitochondria the matrix concentration of succinate is not
identical to the one applied, since it is inﬂuenced by the activities
of the dicarboxylate carrier and other TCA cycle enzymes) and
(4) uncoupled SMP do not produce superoxide at complex I due to
RET (this readily occurs in intact mitochondria especially at higher
succinate concentrations and complicates the interpretation of the
Fig. 1. Complex II produces ROS at subsaturating succinate concentrations upon inhibition of ubiquinone reductase activity. The total ROS production of SMP prepared from bovine
heart mitochondria (0.12 mg protein ml−1) was measured as H2O2 production in the presence of 400 U ml−1 SOD and using the Ampliﬂu Red™ assay as described in the Material
and methods section. In general, mean values of three measurements and standard deviations (S.D.) are shown. (Α) The succinate oxidase of SMP was fueled by different concen-
trations of succinate (as indicated) and the effect of the complex II Q-site inhibitor atpenin A5 (50 nM) and the complex III Qo-site inhibitor stigmatellin (1 μM) on H2O2 production
was determined. 1.5 mM malonate that binds competitively to the dicarboxylate site of complex II suppressed ROS production. (B) Effect of different succinate concentrations
(0.01–5 mM) on the atpenin A5 induced ROS production. (C) The effect of different atpenin A5 concentrations on ROS production (ﬁlled circles, continuous line) and succinate ox-
idase activity (open circles, dashed line) were compared. In both experiments, SMP were fueled by 100 μM succinate. The succinate oxidase activity (100% were equal to an oxygen
consumption of 78.9 nmol O2 min−1 mg−1) of SMP (0.12 mg protein ml−1) was measured with an Oxygrap-2k as detailed in the Material and methods section. Mean values of
duplicates are shown. (D) Induction of the succinate-supported ROS-production by different complex II Q-site inhibitors. Succinate was supplied in the range of 0.1 to 5 mM.
Complex II inhibitors were present at the following concentrations: 250 nM atpenin A5 (inhibiting the succinate oxidase by 98%), 100 μM TTFA (inhibiting the succinate oxidase
by 61%), 100 μM diazoxide (inhibiting the succinate oxidase by 38%) and 1.5 mM malonate (inhibiting succinate oxidase in the range of 100% in the presence of 100 μM succinate
to 94.5% in the presence of 5 mM succinate).
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of SMP was determined as the H2O2 production in the presence of SOD
with the Ampliﬂu Red™/HRP assay (Fig. 1A). The unspeciﬁc back-
ground rate in the absence of SMP could be neglected. In agreement
with our previous investigations [13,14], uninhibited SMP produced
H2O2 at a very low rate, also at subsaturating succinate concentrations.
When the succinate oxidase of the SMPwas inhibited by the addition of
the complex III inhibitor stigmatellin [37] or the speciﬁc complex II
Q-site inhibitor atpenin A5 [38], a largely increased H2O2 production
could be observed at subsaturating succinate concentrations (Fig. 1A).
Both inhibitors block the electron transfer from the terminal
FeS-cluster onto ubiquinone, i.e. the ubiquinone reductase activity
of complex II: atpenin A5 directly by competition with ubiquinone
[38,39], the complex III inhibitor stigmatellin indirectly by preventing
the reoxidation of ubiquinol to ubiquinone that is then no longer avail-
able for this reaction. The ROS production peaked at around 100 μM
succinate and declined with increasing and decreasing succinateconcentrations (Fig. 1A and B). This concentration is close to the Km
value (130 μM) of succinate that has been determined for puriﬁed com-
plex II isolated from bovine heart mitochondria [40] indicating that the
ROS production under these conditions is maximal around half satura-
tion of the dicarboxylate site. The H2O2 production was completely
suppressed by the competitive succinate analogue malonate. The con-
temporaneous presence of 1 μMDQA, a high afﬁnity complex I inhibitor
[41], had no affect on the ROS production (results not shown), exclud-
ing any contribution of complex I. The H2O2 production in the presence
of 1 μM stigmatellin was about 2.5-times higher than the H2O2 produc-
tion in the presence of 50 nM atpenin A5 (Fig. 1A). The Qo-site of com-
plex III could be excluded as a ROS source since binding of stigmatellin
prevents the formation of superoxide at this site [15,42]. Our previous
study had shown that 50 nM atpenin A5 was sufﬁcient to completely
inhibit the succinate-oxidase activity of SMP [14]. However, when we
titrated the inhibitory activity of atpenin A5 with the present batch of
SMP and 100 μM succinate (Fig. 1C), we observed that 50 nM inhibited
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oxidase and the atpenin A5 induced H2O2 production could be
increased by higher inhibitor concentrations (Fig. 1C). At 250 nM
atpenin A5, the complex II activity was inhibited by ~98% and the
H2O2 production reached values around 1500 pmol min−1 mg−1.
This was still about 40% lower than the complex II dependent
(i.e. malonate-sensitive) H2O2 production in the presence of the com-
plex III inhibitor stigmatellin (Fig. 1A). Since the succinate-oxidase
was completely inhibited by 1 μM stigmatellin (results not shown),
we checked if this additional inhibition of the succinate-oxidase was re-
sponsible for the increased H2O2 production. However, when 250 nM
atpenin A5 and 1 μM stigmatellin were both present, the detected
H2O2 production was somewhat lower than the rate in the presence
of 250 nM atpenin A5 alone (results not shown). This indicates that
the highest rates of ROS production at complex II occurred when the
electron ﬂow was blocked at a site further downstream of the
Q-binding site of complex II. Also other inhibitors of complex II that
bind to the Q-site like TTFA and diazoxide induced ROS production at
subsaturating succinate concentrations (Fig. 1D). The lower rates of
H2O2 production corresponded well to the lower inhibitory potential
of both substances (100 μM TTFA inhibited succinate oxidase by 61%,
100 μM diazoxide by 38%). Inhibition of more than 60% of the ubiqui-
none:reductase activity seems to be a prerequisite to produce a signiﬁ-
cant rate of ROS by complex II— at least when electrons are supplied by
succinate in the ‘forward mode’.
3.2. Complex II mainly produces hydrogen peroxide upon inhibition of
the ubiquinone–reductase activity
Next, we investigated whether mitochondrial complex II produces
mainly superoxide or hydrogen peroxide as primary ROS. The gener-
ation of membrane-impermeable superoxide could not be detected
with intact mitochondria [30], since it is probably mainly released
into the mitochondrial matrix. With SMP, we measured the superox-
ide production as the SOD-sensitive reduction of acetylated cyto-
chrome c and the total ROS production with the Ampliﬂu Red™
assay in the presence of SOD (Fig. 2). The primary H2O2 production
can be deduced by subtracting the superoxide production from the
total ROS production. To allow direct comparison of both rates, they
are expressed as electron equivalents transferred onto molecular
oxygen, i.e. 1 e− per O2•− and 2 e− per H2O2, respectively. In theFig. 2. Complex II with inhibited ubiquinone reductase produces mainly hydrogen peroxi
25 μM acetylated cytochrome c and total ROS production as H2O2 production in the prese
are expressed as the transfer of electron equivalents onto O2, i.e. one e− per superoxide an
generally fueled by 100 μM succinate, inhibitors were added in the following concentration
measurements and standard deviations (S.D.) are shown.presence of 100 μM succinate, the inhibition of complex II by atpenin
A5 or a further downstream block by stigmatellin induced mainly the
production of H2O2 (Fig. 2). The rate of superoxide production at
pH 7.2 corresponded to about 21–26% of the total ROS production.
At pH 8.0 the overall rate of ROS generation as well as the fraction
of superoxide (about 29–31%) increased slightly under the applied
conditions. This can be explained by the higher activity of complex
II at pH 8.0 [40] and the increased stability of the superoxide anion
at basic pH [43]. The data indicate that complex II with inhibited
ubiquinone reductase activity mainly produces H2O2 at physiological
pH values.
3.3. Attenuation of the complex II-dependent ROS-production by competitive
TCA cycle intermediates
Prior investigations indicate that ROS are only produced by the ﬂavin
when the dicarboxylate site is unoccupied [29,30]. Since other TCA me-
tabolites also are known to bind competitively to the dicarboxylate site
of complex II [44–46], we checked how these substances inﬂuence the
ROS production. First we analyzed the effect of fumarate, the product
of succinate oxidation that binds with comparable afﬁnity to the
dicarboxylate site [27,40]. Also fumarate attenuated the atpenin A5
(Fig. 3A) and stigmatellin (Fig. 3B) induced ROS generation in a concen-
tration dependent manner. Considering the similar afﬁnity of both car-
boxylates, fumarate was more effective than succinate. For example the
H2O2 production in the presence of 0.1 mM succinate and 0.1 mM fuma-
rate (total carboxylate concentration 0.2 mM) was lower than in the
presence of 0.1 mM fumarate and 0.5 mM succinate (total carboxylate
concentration 0.6 mM) or 0.5 mM succinate alone (Fig. 3). These results
suggest that fumarate attenuated theROS generation by twodistinguish-
able effects: (1) by occupying the dicarboxylate binding site and (2) by
changing the redox potential of the succinate/fumarate pair which in
turn should affect the redox states of all electron-transferring cofactors
of complex II. Hence, it can be concluded that the more reduced the
cofactors the higher is the rate of ROS generation.
Also other TCA cycle intermediates, namely malate, citrate and
especially oxaloacetate that are known to bind competitively to the
dicarboxylate site attenuated the stigmatellin and atpenin A5 induced
ROS production (Fig. 4). Whenwe titrated the inhibitory effect of malate
(Fig. 4B) and oxaloacetate (Fig. 4C) on the atpenin A5-induced ROS gen-
eration and compared it to the inhibition of the succinate-oxidasede. The superoxide production of SMP was determined as SOD-sensitive reduction of
nce of 400 U ml−1 SOD as described in the Material and methods section. Both rates
d two e− per H2O2. The ROS production was determined at pH 7.2 and 8.0. SMP were
s: 1 μM stigmatellin, 250 nM atpenin A5 and 1.5 mM malonate. Mean values of three
Fig. 3. Fumarate attenuates the ROS production of complex II. The determination of the H2O2 production and general conditions were the same as described in Fig. 1. (A) ROS pro-
duction induced by 50 nM atpenin A5 was determined at different concentrations and ratios of the dicarboxylates succinate and fumarate. (B) General conditions as in (A), ROS
production was induced by 1 μM stigmatellin. Mean values of three measurements and standard deviations (S.D.) are shown.
1160 I. Siebels, S. Dröse / Biochimica et Biophysica Acta 1827 (2013) 1156–1164reﬂecting the complex II activity in SMP, we observed a remarkable con-
gruence. Some discrepancywas only observed formalate concentrations
above 1 mM. This could be attributed to the fact that on the one hand
malate can be oxidized by complex II and therefore serves as a substrate
of the complex II dependent oxidase activity of SMP [45–47]. On the
other hand, the oxidation product of this reaction is the enol-form of
oxaloacetate [47], a potent complex II inhibitor. This is also obvious
from Fig. 4C that shows a half-maximal inhibition of the atpenin
A5-induced ROS production and the succinate-oxidase by ~0.25 μM
oxaloacetate.
3.4. Complex II is an independently inducible ROS generator
Finally, we checked, whether other respiratory chain complexes,
especially complex I, the major electron supplier of the respiratory
chain, affect the ROS generation by complex II. For this purpose, we
analyzed the effect of various respiratory chain inhibitors on ROS gen-
eration when electrons were supplied exclusively by 250 μM NADH
or 100 μM succinate or when both substrates were simultaneously
present (Fig. 5). The DQA-induced ROS-generation at complex I was
not inﬂuenced by the complex II inhibitors malonate and atpenin
A5 that also had no inhibitory effect on the NADH-oxidase (results
not shown). Conversely, the complex I inhibitor DQA had neither an
effect on the atpenin A5 induced H2O2-generation in the presence of100 μM succinate (Fig. 5) nor on the succinate-oxidase (results not
shown). The concurrent presence of NADH somewhat reduced the
atpenin A5 induced ROS-production, indicating that the redox-state
of the Q-pool might have a minor effect under the applied conditions,
i.e. that ubiquinol might be more effective than ubiquinone in
displacing atpenin A5 in the Q-site. The maximal rate of H2O2 produc-
tion measured in the presence of both substrates, 1 μM DQA and 250
nM atpenin A5 (13.7 nmol min−1 mg−1) was quite similar to the
sum of the individually induced rates (12.5 nmol min−1 mg−1).
These data indicate that complex II is an independently inducible
ROS generator.
4. Discussion
Studying the molecular mechanisms of the mitochondrial ROS
production is a timely topic [6], since it is becoming more and more
evident that mitochondria-derived ROS are not only involved in the
onset and progression of several diseases, but can also act as indis-
pensable signalingmolecules under non-pathological conditions [4,5].
It is also increasingly recognized that the sites of mitochondrial ROS
production are inherently connected via a network of metabolic
pathways and regulatory processes and that factors causing a
down-regulation of ROS at one mitochondrial site might increase
the ROS production at another site. A prime example is mammalian
Fig. 4. Attenuation of the ROS production by different competitively binding TCA cycle intermediates. Determination of H2O2 production and general conditions were the same as in
Fig. 1. Succinate was generally added at a concentration of 100 μM. (A) ROS production of complex II was induced by the addition of 1 μM stigmatellin or 250 nM atpenin A5.
Dicarboxylates were added at 5 mM (malate and citrate), the inhibitor malonate at 1.5 mM, respectively. (B) Effect of different malate concentrations (0.1–5 mM) on the ROS pro-
duction induced by 250 nM atpenin A5 (ﬁlled circles, continuous line) and the succinate oxidase (100% were equal to an oxygen consumption of 74.7 nmol O2 min−1 mg−1; open
diamonds, dashed line). (C) Effect of different oxaloacetate concentrations (0.01–20 μM) on ROS production induced by 250 nM atpenin A5 (ﬁlled circles, continuous line) and suc-
cinate oxidase activity (100% were equal to an oxygen consumption of 72.7 nmol O2 min−1 mg−1; open diamonds, dashed line). Mean values of three measurements and standard
deviations (S.D.) are shown for ROS production, mean values of duplicates are shown for succinate oxidase activity.
1161I. Siebels, S. Dröse / Biochimica et Biophysica Acta 1827 (2013) 1156–1164complex II [7] that can – under speciﬁc conditions – modulate the
ROS production of complexes I and III in an ambivalent way [13,14]
and can act – as recently shown by the investigation of Quinlan and
colleagues [30] – as a signiﬁcant source of ROS. This multifaceted in-
terplay between complex II activity and ROS is also obvious from the
role of complex II in the development of speciﬁc forms of cancer. On
the one hand it is a plausible hypothesis that cancer associated complex
II mutations increase themitochondrial ROS production [19,22]. On the
other hand complex II Q-site inhibitors likeα-tocopheryl succinate [48]
and mitochondrially targeted vitamin E succinate (MitoVES) [49,50]
can be used to speciﬁcally induce cell death of cancer cells which in-
volves the production of ROS [24,25]. To understand the role of complex
II three key questions have to be answered: (1) What is/are the site(s)
of ROS production, (2) which factors inﬂuence (i.e. promote or
attenuate) the ROS production and (3) under which physiological and
pathophysiological conditions does this occur.
Two sites have been proposed as the primary ROS source within
mitochondrial complex II and related enzymes (SQRs and QFRs), the
covalently bound FAD and the Q-site. The Q-site has been proposed
based on studies in Saccharomyces cerevisiae [51,52] and a mixedcontribution of FAD and the Q-site was suggested for complex II
from the parasitic nematode Ascaris suum [53]. While a contribution
of the Q-site seems reasonable for some Q-site mutants [54–57], the
most likely source of ROS in functional complex II is the bound FAD
[28–30,58]. This notion is supported by the trend of the succinate-
dependent ROS generation [29,30] (Fig. 1B) and the differential effect
of inhibitors that bind to the dicarboxylate and ubiquinone binding
site, respectively (Fig. 6). It has to be noticed that E. coli SQR produces
ROS in the absence of quinone-binding site inhibitors [29,30]
while mammalian complex II only produces ROS in the forward mode
(i.e. electrons are supplied by succinate) when its ubiquinone reductase
activity is inhibited (Fig. 6A). Anyway, ROS production of both enzymes
showed a similar dependence on the succinate concentration [29,30]
(Fig. 1B). The trend of the succinate-dependent ROS production can be
explained by a model that postulates two antithetic effects of succinate
binding: on the one hand succinate binding is a prerequisite for the re-
duction of the redox-groups including the FAD that is presumably the
primary source of ROS. This implies that increasing substrate concentra-
tions cause an increasing ROS production (Fig. 6B). On the other hand,
succinate binding hampers at the same time access of oxygen to the
Fig. 5. Complex II is an independently inducible ROS generator. Determination of H2O2 production and general conditions were the same as in Fig. 1. The respiratory chain of SMP
was either fueled by 250 μM NADH, 100 μM succinate or a combination of both substrates. Inhibitors were present at: 1 μM DQA, 250 nM atpenin A5 and 1.5 mM malonate. Mean
values of three measurements and standard deviations (S.D.) are shown.
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duction at saturating substrate concentrations. Since the kinetics of the
succinate dehydrogenase reaction can be described by the Michaelis–
Menten model, the trend of the succinate-dependent ROS-production
can be simulated by superimposing two hyperbolic curves, one
representing the succinate-dependent reduction of FAD and one
inverted describing the succinate-dependent block of the oxygen access
to the FAD (Fig. 6B). The resulting graph describes approximately theFig. 6. Proposed model for ROS production of complex II. The model summarizes the ﬁndin
structure of complex II and the site of ROS production. SdhA–D indicate the 4 subunits of com
as black circles ([FeS]-clusters), a tricyclic structure (FAD), a stretched white hexagon (Q-site
b). Upon binding of atpenin A5 to the Q-site, transfer of electrons is blocked and upstream
also some superoxide) can be only produced from FADH2 if the dicarbocylate site is unoccup
affects ROS generation by increasing the redox potential of the fumarate/succinate couple. (
the Michaelis–Menten type kinetic of the succinate–dehydrogenase reaction. Increasing suc
ROS production. At the same time, the binding of succinate to the dicarboxylate site hampe
determine the ROS production (indicated by the solid line) at different succinate concentra
itively to this substrate site can block the access of oxygen to the FADH2. This supports thaexperimental results of the present and a previous study [30]: an in-
crease at very low succinate concentrations, peaking at subsaturating
succinate and a decrease at higher concentrations. Such a behavior
would be hardly expected if the Q-site would be the primary ROS
source, since in this case an increasing appearance of the ubiquinone
species responsible for the ROS production, in this case most likely a
semiquinone, should be promoted by increasing substrate concentra-
tions. In addition, the present and a previous [30] study show that allgs of the present and some previous investigations (for details see text). (A) General
plex II. The relative positions of the prosthetic groups and functional sites are indicated
), a white rectangle (dicarboxylate binding site) and a schematic porphyrin ring (heme
redox-groups including the FAD become reduced. ROS (mainly hydrogen peroxide, but
ied. Also the binding of fumarate prevents the production of ROS. Fumarate additionally
B) The trend of succinate-dependent ROS-production of complex II can be explained by
cinate concentrations cause increased reduction of the FAD which is a prerequisite for
rs access of oxygen with inverse concentration dependence. The two antithetic effects
tions. (C) Besides succinate and fumarate, also other dicarboxylates that bind compet-
t view that ROS are only produced if the dicarboxylate site is empty.
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dicarboxylate site of complex II attenuated ROS productionwhile all in-
hibitors that bind to the Q-site of complex II increased ROS generation.
At least a partial contribution of the Q-site or the [3Fe–4S] cluster might
be conveyed from the fact that the ROS production in the presence of
atpenin A5 was about 40% lower than in the presence of stigmatellin
that blocks the respiratory chain further downstream at the Qo-site of
complex III. Such a reduction has been also observed by Quinlan et al.
in intact skeletal rat mitochondria [30]. In the latter study it was
shown that binding of atpenin A5 altered the catalytic properties of
the dicarboxylate site causing a 25–45% decreased succinate dehydro-
genase activity [30] which might account for the reduced ROS produc-
tion. While our study strongly suggest that the FAD is a more likely
site of ROS production – at least when the ubiquinone:reductase activ-
ity of complex II is inhibited – the data cannot exclude a partial contri-
bution of the [3Fe4S] cluster or the Q-site.
Furthermore, the present study revealed that mitochondrial com-
plex II with inhibited ubiquinone reductase activity mainly produces
hydrogen peroxide as the primary reactive oxygen species. This is in
contrast to E. coli SQR that produces almost exclusively superoxide
[29]. The related E. coli QFR produced a mixture of superoxide and hy-
drogen peroxide that was shifted towards hydrogen peroxide at succi-
nate concentrations above 1 mM [29]. Messner and Imlay concluded
that QFR releases superoxide from the fully reduced ﬂavin if the
oxidized [2Fe–2S] cluster is available to sequester the semiquinone
electron; otherwise this electron is rapidly transferred to the nascent
superoxide and hydrogen peroxide is released. Yankovskaya et al. [58]
suggested that the differential arrangement of redox potentials among
the redox centers in E. coli SQR and QFR determines the rate and
ROS preference at the ﬂavin site. In SQR the high potential centers
([3Fe–4S] and heme b, which attract electrons and pull them away
from the dicarboxylate site) are close to the Q-site, while in QFR, FAD
and the [2Fe–2S] clusters have the highest redox potentials and hence
accumulate electrons close to the dicarboxylate binding site. Having
these considerations in mind, we found that the observed discrepancy
between mammalian complex II and E. coli SQR can be related to the
presence/absence of the Q-site inhibitor atpenin A5. In the presence of
atpenin A5, the [2Fe–2S] cluster and the FAD should become much
more reduced than in its absence which favors the formation of hydro-
gen peroxide over the release of superoxide. This would also imply that
the fully reduced ﬂavin is the primary source of ROS.
The general inﬂuence of the redox state of complex II cofactors on the
rate of ROS production is also obvious from the measurements at differ-
ent succinate/fumarate ratios. Both dicarboxylates bind with similar af-
ﬁnity to the dicarboxylate site of complex II [27,40], but fumarate has a
more pronounced attenuating effect on ROS production. In the presence
of atpenin A5 the redox state of the electron-transferring centers should
be inﬂuenced by the preset potential of the succinate/fumarate couple
and hence it can be deduced that the more reduced the redox centers
are, the higher the rate of ROS production. The investigations of Messner
and Imlay [29] and Yankovskaya et al. [58] implicate that also the redox
states of the centers downstream of FAD modulate ROS production. In
this regard, it might also matter whether the Q-site is occupied by an in-
hibitor or a ubiquinonemolecule, which in turnmight give an alternative
explanation for the differentmaximal rates in the presence of atpenin A5
and stigmatellin.
An important ﬁnding of this and the previous investigation of
Quinlan and colleagues [30] is that complex II can be a substantial
source of ROS in the presence of 25–500 μM succinate. Concentra-
tions in this range have been estimated for different tissues and mito-
chondria under normoxic conditions [59–62]. This means that any
complex II Q-site inhibitor should in principle immediately induce
the production of ROS from the ﬂavin site. However, the ROS produc-
tion is at least partly suppressed by other dicarboxylates that can bind
competitively to the binding site of complex II (Fig. 6C). Especially
oxaloacetate can effectively suppress ROS production by complex II.Inhibition of complex II also suppresses superoxide production at
complex I by reverse electron transfer, indicating that oxaloacetate
could be an important modulator of the mitochondrial ROS produc-
tion under physiological conditions [12]. Finally, we showed that
complex II is an independently inducible ROS generator that is not di-
rectly affecting the activity of the other respiratory chain complexes,
although an indirect inﬂuence via the TCA cycle has to be considered.
This might have important implications for the development of anti-
cancer drugs targeted against the Q-site of complex II [24,25].
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